financetom
Business
financetom
/
Business
/
Teck Resources Retains Outperform Rating, $83 Price Target at National Bank of Canada
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Teck Resources Retains Outperform Rating, $83 Price Target at National Bank of Canada
Jul 5, 2024 8:38 AM

11:24 AM EDT, 07/05/2024 (MT Newswires) -- National Bank of Canada on Friday reiterated its outperform rating on the shares Teck Resources ( TECK ) and its $82.50 price target after the approval of the US$6.9 billion sale of its 77% stake in steelmaking coal business Elk Valley Resources to Glencore.

The transaction is now expected to close July 11.

"Our Outperform rating is based on Teck's strong financial position and robust copper growth pipeline," analyst Shane Nagle wrote.

Nagle said Teck plans to use the proceeds to repurchase US$2.0 billion of class B subordinate voting shares and pay a special dividend of $0.50 per share on both Class A and Class-B shares.

National Bank said Teck will return US$2.6 billion ($3.5 billion) in total cash including a $500 million buyback, within its expected range of $3 billion-$4 billion.

Teck will also reduce its debt by US$2.0 billion through a cash tender offer of US$1.25 billion to repurchase certain notes.

Price: 69.92, Change: +0.97, Percent Change: +1.41

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Jun 14, 2024
05:10 AM EDT, 06/14/2024 (MT Newswires) -- Editas Medicine ( EDIT ) said Friday that new data in a phase 1/2 trial of its gene-editing cell therapy medicine renizgamglogene autogedtemcel showed its was well-tolerated and had a safety profile consistent with other treatments of patients with sickle-cell disease, a blood disorder. The company describes the drug, also called reni-cel, as...
Pfizer's Phase 2 MagnetisMM-3 Study of ELREXFIO Shows Median Overall Survival of Over 2 Years
Pfizer's Phase 2 MagnetisMM-3 Study of ELREXFIO Shows Median Overall Survival of Over 2 Years
Jun 14, 2024
05:21 AM EDT, 06/14/2024 (MT Newswires) -- Pfizer ( PFE ) said Friday that results from the phase 2 MagnetisMM-3 study of ELREXFIO in patients with heavily pretreated relapsed or refractory multiple myeloma showed a median overall survival of 24.6 months, with median progression-free survival of 17.2 months. After more than two years of follow-up in the MagnetisMM-3 trial, the...
Ultragenyx Pharmaceutical Prices $350 Million Offering
Ultragenyx Pharmaceutical Prices $350 Million Offering
Jun 14, 2024
05:18 AM EDT, 06/14/2024 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) said late Thursday it has priced an underwritten public offering of 7.4 million common shares at $39 per share for expected gross proceeds of about $350 million. The company is offering pre-funded warrants, in lieu of common stock to certain investors, to purchase about 1.5 million shares at...
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials
Jun 14, 2024
05:13 AM EDT, 06/14/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Friday its Casgevy gene-editing therapy demonstrated clinical benefits in trials in sickle cell disease and transfusion-dependent beta thalassemia. In sickle cell disease, about 92% of evaluable patients were shown to be free from vaso-occlusive crises, or VOCs, for at least 12 months, while 97% of patients with...
Copyright 2023-2026 - www.financetom.com All Rights Reserved